JP2021535107A - Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法 - Google Patents

Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法 Download PDF

Info

Publication number
JP2021535107A
JP2021535107A JP2021509744A JP2021509744A JP2021535107A JP 2021535107 A JP2021535107 A JP 2021535107A JP 2021509744 A JP2021509744 A JP 2021509744A JP 2021509744 A JP2021509744 A JP 2021509744A JP 2021535107 A JP2021535107 A JP 2021535107A
Authority
JP
Japan
Prior art keywords
mutation
migalastat
patient
salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021509744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535107A5 (cg-RX-API-DMAC7.html
Inventor
エルフリダ ベンジャミン,
Original Assignee
アミカス セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65279726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2021535107(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アミカス セラピューティックス インコーポレイテッド filed Critical アミカス セラピューティックス インコーポレイテッド
Publication of JP2021535107A publication Critical patent/JP2021535107A/ja
Publication of JP2021535107A5 publication Critical patent/JP2021535107A5/ja
Priority to JP2023071652A priority Critical patent/JP7784398B2/ja
Priority to JP2025117816A priority patent/JP2025165955A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021509744A 2018-08-20 2019-01-16 Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法 Pending JP2021535107A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023071652A JP7784398B2 (ja) 2018-08-20 2023-04-25 Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP2025117816A JP2025165955A (ja) 2018-08-20 2025-07-14 Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719962P 2018-08-20 2018-08-20
US62/719,962 2018-08-20
PCT/US2019/013761 WO2020040806A1 (en) 2018-08-20 2019-01-16 Methods of treating fabry disease in patients having a mutation in the gla gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023071652A Division JP7784398B2 (ja) 2018-08-20 2023-04-25 Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Publications (2)

Publication Number Publication Date
JP2021535107A true JP2021535107A (ja) 2021-12-16
JP2021535107A5 JP2021535107A5 (cg-RX-API-DMAC7.html) 2022-02-24

Family

ID=65279726

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021509744A Pending JP2021535107A (ja) 2018-08-20 2019-01-16 Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP2023071652A Active JP7784398B2 (ja) 2018-08-20 2023-04-25 Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP2025117816A Pending JP2025165955A (ja) 2018-08-20 2025-07-14 Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023071652A Active JP7784398B2 (ja) 2018-08-20 2023-04-25 Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP2025117816A Pending JP2025165955A (ja) 2018-08-20 2025-07-14 Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Country Status (25)

Country Link
US (2) US12594268B2 (cg-RX-API-DMAC7.html)
EP (7) EP3840753B1 (cg-RX-API-DMAC7.html)
JP (3) JP2021535107A (cg-RX-API-DMAC7.html)
KR (3) KR102982790B1 (cg-RX-API-DMAC7.html)
CN (1) CN112888439A (cg-RX-API-DMAC7.html)
AU (2) AU2019326252A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003137A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110065A1 (cg-RX-API-DMAC7.html)
CL (3) CL2021000435A1 (cg-RX-API-DMAC7.html)
DK (1) DK3840753T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190569A1 (cg-RX-API-DMAC7.html)
ES (1) ES2993833T3 (cg-RX-API-DMAC7.html)
FI (1) FI3840753T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241454T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068783T2 (cg-RX-API-DMAC7.html)
IL (2) IL325185A (cg-RX-API-DMAC7.html)
LT (1) LT3840753T (cg-RX-API-DMAC7.html)
MX (2) MX2021002070A (cg-RX-API-DMAC7.html)
PL (1) PL3840753T3 (cg-RX-API-DMAC7.html)
PT (1) PT3840753T (cg-RX-API-DMAC7.html)
RS (1) RS66094B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101117QA (cg-RX-API-DMAC7.html)
SI (1) SI3840753T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400436T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020040806A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
CN113969313A (zh) * 2021-11-29 2022-01-25 百世诺(北京)医学检验实验室有限公司 罕见遗传病突变基因及其应用
CN116656704B (zh) * 2023-06-01 2024-11-05 华东理工大学 用于治疗法布里病的转基因表达盒
CN116622750B (zh) * 2023-06-01 2024-05-31 上海勉亦生物科技有限公司 优化的人法布里转基因表达盒及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
PL2027137T3 (pl) 2005-06-08 2015-08-31 Amicus Therapeutics Inc Oczyszczanie imino- i aminocukrów
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
AU2008245578A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
US8321148B2 (en) 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
EP2435459B1 (en) 2009-05-26 2016-05-04 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of acid beta-glucosidase
EP2502068B1 (en) 2009-11-17 2016-02-10 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
WO2012125402A2 (en) 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
US20120283290A1 (en) 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
WO2013091897A1 (en) 2011-12-22 2013-06-27 Centogene Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
EP2874648A4 (en) 2012-07-17 2015-12-30 Amicus Therapeutics Inc ALPHA GALACTOSIDASE A AND 1-DEOXYGALACTONO JIRIMYCIN CO FORMULATION
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014120900A1 (en) * 2013-01-31 2014-08-07 Icahn School Of Medicine At Mount Sinai Enhanced therapeutic regimens for treating fabry disease
US20170051267A1 (en) 2015-08-20 2017-02-23 Research Foundation Of The City University Of New York Novel alpha-galactosidase a derivatives
EP3432882B1 (en) 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
WO2018017721A1 (en) 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
US11357834B2 (en) 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EA202090242A1 (ru) 2017-07-19 2020-05-26 Амикус Терапьютикс, Инк. Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
WO2019046244A1 (en) 2017-08-28 2019-03-07 Amicus Therapeutics, Inc. METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
AU2019217603A1 (en) 2018-02-06 2020-09-24 Amicus Therapeutics, Inc. Treatment of patients with classic Fabry disease
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
TW202042812A (zh) * 2019-01-22 2020-12-01 美商阿米庫斯醫療股份有限公司 減少法布瑞氏症患者中之腦血管事件之方法
US20220313670A1 (en) 2019-06-11 2022-10-06 Amicus Therapeutics, Inc. Methods Of Treating Fabry Disease In Patients Having Renal Impairment
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
HRP20260399T1 (hr) * 2020-02-10 2026-05-08 Amicus Therapeutics, Inc. Postupci liječenja fabryjeve bolesti
FI4114390T3 (fi) * 2020-03-06 2025-03-07 Amicus Therapeutics Inc Menetelmiä fabryn taudin hoitamiseksi potilaissa, joilla on mutaatio gla-geenissä

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENJAMIN, ELFRIDA R: "The validation of pharmacogenetics for the identification of Fabry patients to be treated with migal", GENETICS IN MEDICINE, vol. 19, no. 4, JPN6022044785, 2017, pages 430 - 438, ISSN: 0005113950 *
LUKAS J: "Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease", HUM. MUTAT., vol. 37, no. 1, JPN6022044786, 2016, pages 43 - 51, ISSN: 0004905123 *

Also Published As

Publication number Publication date
MX2024008350A (es) 2024-07-19
IL280961A (en) 2021-04-29
SMT202400436T1 (it) 2024-11-15
EP3840753B1 (en) 2024-07-24
KR102982790B1 (ko) 2026-06-26
CL2021000435A1 (es) 2021-10-22
EP3840753A1 (en) 2021-06-30
KR20210046729A (ko) 2021-04-28
IL325185A (en) 2026-02-01
WO2020040806A1 (en) 2020-02-27
KR20240017128A (ko) 2024-02-06
MX2021002070A (es) 2021-07-15
CA3110065A1 (en) 2020-02-27
SI3840753T1 (sl) 2025-01-31
FI3840753T3 (fi) 2024-10-30
HUE068783T2 (hu) 2025-01-28
CN112888439A (zh) 2021-06-01
AU2019326252A1 (en) 2021-02-25
BR112021003137A2 (pt) 2021-05-11
EP4289476A2 (en) 2023-12-13
IL280961B1 (en) 2026-01-01
EP4282472A2 (en) 2023-11-29
EA202190569A1 (ru) 2021-06-01
JP2025165955A (ja) 2025-11-05
EP4289476A3 (en) 2024-02-21
EP4285991A3 (en) 2024-02-21
CL2024000741A1 (es) 2024-10-04
DK3840753T3 (da) 2024-10-28
KR102982792B1 (ko) 2026-06-25
EP4285990A3 (en) 2024-02-21
EP4299117A2 (en) 2024-01-03
JP2023106398A (ja) 2023-08-01
EP4285990A2 (en) 2023-12-06
EP4285991A2 (en) 2023-12-06
PL3840753T3 (pl) 2025-01-20
LT3840753T (lt) 2024-11-11
EP4299117A3 (en) 2024-02-21
PT3840753T (pt) 2024-10-30
US20240277687A1 (en) 2024-08-22
KR20240017127A (ko) 2024-02-06
EP4282472A3 (en) 2024-02-21
AU2025205141A1 (en) 2025-07-31
US12594268B2 (en) 2026-04-07
ES2993833T3 (en) 2025-01-10
RS66094B1 (sr) 2024-11-29
IL280961B2 (en) 2026-05-01
EP4289475A2 (en) 2023-12-13
SG11202101117QA (en) 2021-03-30
JP7784398B2 (ja) 2025-12-11
EP4289475A3 (en) 2024-02-21
CL2024000739A1 (es) 2024-10-04
HRP20241454T1 (hr) 2024-12-20
US20210315875A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
JP6788725B2 (ja) 腎機能障害を有するファブリー患者の治療方法
US20240277687A1 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
JP7098529B2 (ja) Gla遺伝子にg9331a変異を有する患者においてファブリー病を処置する方法
JP7755929B2 (ja) ファブリー病患者における心臓機能の強化及び/または安定化方法
JP2022536687A (ja) 腎機能障害を有する患者のファブリー病を治療する方法
JP2021512896A (ja) 古典型ファブリー病患者の治療
JP7749572B2 (ja) Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP7680356B2 (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
JP2024525760A (ja) 小児患者のファブリー病を治療する方法
HK40104071A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40105450A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104441A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104764A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104069A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40122460A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40057125A (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
HK40057125B (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20210517

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20210517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250718